Vitamin D linked to MS progression

Researchers from the Harvard School of Public Health measured serum concentrations of 25-hydroxyvitamin D among a total of 465 participants in 18 European countries as well as Israel and Canada who were taking part in a clinical trial originally designed to look at the impact of early versus delayed interferon beta-1b treatment in those with a first event suggestive of MS.